Trials / Completed
CompletedNCT00038519
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 16 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amprenavir/ritonavir | |
| DRUG | Saquinavir/ritonavir |
Timeline
- Start date
- 2001-04-01
- First posted
- 2002-06-03
- Last updated
- 2006-07-28
Locations
52 sites across 10 countries: United States, Argentina, Brazil, Canada, France, Italy, Poland, Puerto Rico, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00038519. Inclusion in this directory is not an endorsement.